Clinical Scorecard: Efficacy and Safety of Intrapericardial Triamcinolone Injection for Recurrent Pericardial Effusion in Children: A Comprehensive Review

At a Glance

Key Highlights

• Intrapericardial triamcinolone was administered to nine pediatric patients.
• Median age of patients was 21.5 months, with a range from 2 months to 16 years.
• All patients had prior treatment with pericardiocentesis before triamcinolone administration.
• Cytological and microbiological testing of pericardial fluid showed no malignant cells or infections.
• Duration of clinical stability post-triamcinolone varied among patients.

Guideline-Based Recommendations

Diagnosis

• Recurrence of pericardial effusion is defined as fluid buildup after resolution.

Management

• Standard treatments include NSAIDs, colchicine, sclerosing agents, systemic steroids, and pericardiocentesis.

Monitoring & Follow-up

• Echocardiographic imaging to assess effusion size and recurrence.

Risks

• Adverse events associated with systemic corticosteroids include enhanced morbidity and adrenal insufficiency.

Patient & Prescribing Data

Intrapericardial triamcinolone was administered at a dose of 300 mg/m2, with adjustments based on effusion size.

Clinical Best Practices

• Perform pericardiocentesis prior to triamcinolone administration.
• Monitor for systemic side effects post-triamcinolone instillation.

Related Resources & Content

• ESC Guidelines for the Diagnosis and Management of Pericardial Diseases
• Maisch et al. protocol for triamcinolone delivery
• van der Werff et al. study on pediatric post-surgical effusions